Top Markets
#1 Black Phoenix Black Phoenix +360.62%
#2 Islamic Coin Islamic Coin +158.11%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +56.43%
#5 Akedo Akedo +47.69%
#6 BasedHype BasedHype +32.23%
#7 Acurast Acurast +28.01%
#8 Cryptopia Cryptopia +22.04%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.69%
#10 Playnance Playnance +18.61%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Neuropathix, Inc. Neuropathix, Inc.

Neuropathix, Inc.

NPTX
Rank in Stocks #41303
Neuropathix, Inc. is a biopharmaceutical firm dedicated to identifying,... Neuropathix, Inc. is a biopharmaceutical firm dedicated to identifying, advancing, and bringing to market innovative treatments derived from its exclusive platform of synthetic cannabinoid derivatives. The company's efforts are concentrated on the research and preclinical development of chemical compounds like KLS-13019, KLS-13023, and KLS-13022, alongside associated molecules and synthetic cannabidiol-based therapies. These investigational drugs are being explored for their potential application in treating various conditions, including chemotherapy-induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. Previously operating as Kannalife, Inc., the organization rebranded as Neuropathix, Inc. in November 2020. Established in 2010, Neuropathix, Inc. maintains its headquarters in Doylestown, Pennsylvania.
Share Price
$0.0003
Last synced: 2023-06-13
Market Cap
$28.14K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Neuropathix, Inc. (NPTX)

Category

Healthcare
Revenue for Neuropathix, Inc. (NPTX)
Revenue in Aug 2026 TTM: 0
According to Neuropathix, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Neuropathix, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE